-
公开(公告)号：KR1020080050786A
公开(公告)日：2008-06-10
申请号：KR1020060121508
申请日：2006-12-04
Applicant: (주)아모레퍼시픽
IPC: A61K31/133
Abstract: A method for inducing itch and a method for screening an itch inhibiting material using glucosylsphingosine are provided to be useful for studying and understanding the itch, thereby being very usefully used for developing a therapeutic agent for the itch and evaluating the effect of a medicine. A method for inducing itch comprises a step of administering at least one compound selected from the group consisting of glucosylsphingosine and a derivative thereof into an animal except human. A method for screening an itch inhibiting material comprises the steps of: (a) administering an itch inhibition candidate material to an animal where the itch is induced by administering at least one compound selected from the group consisting of the glucosylsphingosine and the derivative thereof; and (b) counting a number when the animal scratches. A method for evaluating the itch inhibition effect comprises the steps of: (a) administering an itch inhibition material to an animal where the itch is induced by administering at least one compound selected from the group consisting of the glucosylsphingosine and the derivative thereof; and (b) counting a number when the animal scratches. A composition for inducing itch comprises at least one compound selected from the group consisting of the glucosylsphingosine and the derivative thereof as an effective ingredient.
Abstract translation: 提供诱导瘙痒的方法和使用葡糖基鞘氨醇来筛选瘙痒抑制物质的方法，可用于研究和理解瘙痒，从而非常有用地用于开发瘙痒治疗剂并评估药物的效果。 诱导瘙痒的方法包括向除人之外的动物中施用至少一种选自葡糖基鞘氨醇及其衍生物的化合物的步骤。 筛选瘙痒抑制物质的方法包括以下步骤：（a）通过施用至少一种选自葡糖基鞘氨醇及其衍生物的化合物，向瘙痒诱导的动物施用瘙痒抑制候选物质; 和（b）当动物划伤时计数。 评估瘙痒抑制效果的方法包括以下步骤：（a）向通过施用至少一种选自葡糖基鞘氨醇及其衍生物的化合物诱导瘙痒的动物施用瘙痒抑制物质; 和（b）当动物划伤时计数。 用于诱导瘙痒的组合物包含至少一种选自葡糖基鞘氨醇及其衍生物的化合物作为有效成分。
-
公开(公告)号：KR1020080034575A
公开(公告)日：2008-04-22
申请号：KR1020060100703
申请日：2006-10-17
Applicant: (주)아모레퍼시픽
IPC: A61K31/047 , A61K31/13
CPC classification number: A61K31/047
Abstract: A method for inhibiting the expression of CCL27/CTACK(Cutaneous T-cell-attracting chemokine) is provided to regulate SPC(sphingosylphosphorylcholine) inducing expression of CCL27/CTACK, so that the method is useful for prevention and treatment of diseases associated with overexpression of CCL27/CTACK including atopic dermatitis, psoriasis and inflammatory skin disease. The expression of CCL27/CTACK is inhibited by administering an effective amount of sphingosylphosphorylcholine regulator capable of inhibiting activity of SPC or competing with the mechanism of SPC inducing overexpression of CCL27/CTACK to a mammal requiring the expression reduction of CCL27/CTACK. A method for screening the SPC regulator comprises the steps of: (1) treating a testing cell such as keratinocyte with 2-10 muM of SPC or its derivatives to induce overexpression of CCL27/CTACK; and (2) treating the overexpression of CCL27/CTACK-induced cell with a candidate material and measuring the expression inhibition of CCL27/CTACK. Further, the mammal has an atopic dermatitis or psoriasis.
Abstract translation: 提供抑制CCL27 / CTACK（皮肤T细胞吸引趋化因子）表达的方法，以调节诱导CCL27 / CTACK表达的SPC（鞘氨醇磷酰胆碱），从而该方法可用于预防和治疗与过表达相关的疾病 CCL27 / CTACK包括特应性皮炎，牛皮癣和炎性皮肤病。 通过施用有效量的能够抑制SPC活性或与诱导CCL27 / CTACK过表达的SPC的机制竞争需要CCL27 / CTACK表达降低的哺乳动物，CCL27 / CTACK的表达被抑制。 用于筛选SPC调节剂的方法包括以下步骤：（1）用2-10μM的SPC或其衍生物处理测试细胞如角质细胞，以诱导CCL27 / CTACK的过度表达; 和（2）用候选物质治疗CCL27 / CTACK诱导的细胞的过度表达，并测量CCL27 / CTACK的表达抑制。 此外，哺乳动物具有特应性皮炎或牛皮癣。
-
公开(公告)号：KR1020070107961A
公开(公告)日：2007-11-08
申请号：KR1020060040588
申请日：2006-05-04
Applicant: (주)아모레퍼시픽
IPC: A61K36/9068 , A61K36/754
CPC classification number: A61K36/00 , A61K8/97 , A61K9/00 , A61K36/754 , A61K36/9062 , A61K36/9068 , A61K2236/33 , A61Q19/00 , A61Q19/005 , Y10S514/857
Abstract: A composition comprising extracts of crude drugs is provided to suppress and relieve itching caused by inflammatory and atopic dermatitis without side effects such as toxicity and skin irritation. A composition for suppressing and relieving itching comprises 0.1-10 wt.% of the extracts of Zingiber officinale Rosc., Evodia officinalis and Alpinia katsumadai Hayata which are prepared by extracting them with water, C1-C4 lower alcohol or a mixed solvent thereof. The daily dosage of crude drug extracts is 0.001-100 mg/kg, preferably 0.1-30 mg/kg and the composition is a pharmaceutical composition having a formulation selected from ointment, plaster, lotion and liniment, or a cosmetic composition having a formulation selected from skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nutrition lotion, massage cream, nutrition cream, moisture cream, hand cream, foundation, essence, nutrition essence, pack, soap, cleansing foam, cleansing lotion, cleansing cream, body lotion and body cleanser.
Abstract translation: 提供包含生药提取物的组合物以抑制和缓解由炎性和特应性皮炎引起的瘙痒，而没有副作用，例如毒性和皮肤刺激。 用于抑制和缓解瘙痒的组合物包括通过用水，C1-C4低级醇或其混合溶剂提取它们制备的姜黄提取物的0.1-10重量％的提取物。 生药提取物的日剂量为0.001-100mg / kg，优选0.1-30mg / kg，并且组合物是具有选自软膏，石膏，洗剂和搽剂的制剂的药物组合物或具有选择的制剂的化妆品组合物 从皮肤洗剂，皮肤柔肤剂，皮肤调色剂，收敛剂，乳液，乳液，滋润乳液，营养乳液，按摩霜，营养霜，保湿霜，护手霜，粉底，精华，营养精华，包装，肥皂，清洁泡沫，清洁 洗剂，清洁霜，身体乳液和身体清洁剂。
-
-
公开(公告)号：KR1020170125780A
公开(公告)日：2017-11-15
申请号：KR1020170146214
申请日：2017-11-03
Applicant: (주)아모레퍼시픽
CPC classification number: C07K14/435 , C07K1/1136 , A61K8/64 , A61K38/18 , A61K38/21 , A61K38/22 , A61K2800/52 , A61Q19/00
Abstract: 본발명은판테놀, 폴리알코올에스터계화합물, 카제인및 그들의유도체로이루어진그룹에서선택된하나이상을포함하는펩타이드또는단백질안정화용조성물을개시한다. 또한펩타이드및 단백질중 하나이상; 및판테놀, 폴리알코올에스터계화합물, 카제인및 그들의유도체로이루어진그룹에서선택된하나이상을포함하는조성물을개시한다. 본발명은펩타이드및 단백질중 하나이상; 및판테놀, 폴리알코올에스터계화합물, 카제인및 그들의유도체로이루어진그룹에서선택된하나이상을혼합하여조성물을제조하는단계를포함하는펩타이드또는단백질안정화방법을개시한다.
Abstract translation: 本发明公开了一种泛醇，多元醇酯化合物，酪蛋白和用于稳定包含至少一种选自由它们的衍生物组成的组中的肽或蛋白质组合物。 至少一种肽和一种蛋白质; 和泛醇，公开了一种多元醇酯化合物，酪蛋白，和组合物包含一种或选自它们的衍生物组成的组中的一种以上。 本发明提供了包含肽和蛋白质中的至少一种的药物组合物; 和泛醇，公开了一种多元醇酯化合物，酪蛋白和肽或蛋白质通过混合选自它们的衍生物中选择的一种或多种方法，包括制备该组合物的步骤稳定化。
-
Patent Agency Ranking26.发明公开
公开(公告)号：KR1020160102722A
公开(公告)日：2016-08-31
申请号：KR1020150025144
申请日：2015-02-23
Applicant: (주)아모레퍼시픽
CPC classification number: A61K8/46 , A61K9/00 , A61Q19/02 , A61Q19/08 , A61K9/0019 , A61K31/185
Abstract: 본발명은히알루론산또는이의유도체의분해를저해시키는조성물에관한것으로서, 보다상세하게는소듐 2-메르캅토에탄설포네이트를함유함으로써히알루로니다제활성에대한저항성이증가된, 히알루론산또는이의유도체의분해억제용조성물, 및상기분해억제용조성물과히알루론산또는이의유도체를함유하는생체투여또는미용성형용조성물, 특히생체조직수복용조성물에관한것이다.
Abstract translation: 本发明涉及用于抑制透明质酸或其衍生物分解的组合物。 更具体地说，本发明涉及用于抑制透明质酸或其衍生物的分解的组合物，其含有2-巯基乙磺酸钠，因此表现出对透明质酸酶活性的增强的抗性。 本发明还涉及用于生物注射或整容手术的组合物，其包含用于抑制分解的组合物或其衍生物，特别是用于生物组织修复的组合物。
-
公开(公告)号：KR101252335B1
公开(公告)日：2013-04-08
申请号：KR1020090065107
申请日：2009-07-16
Applicant: (주)아모레퍼시픽
IPC: A61K8/49 , A61Q19/08 , A61K31/352 , A61P17/18
Abstract: 본 발명은 하기 화학식 1의 화합물, 그것의 이성질체 또는 약제학적으로 허용 가능한 염을 유효 성분으로 포함하는 피부 노화 방지용 조성물에 관한 것이다.
(화학식 1)
본 발명에 따른 조성물에 포함되는 화학식 1의 화합물, 그것의 이성질체 또는 약제학적으로 허용 가능한 염은 피부 자극을 유발하지 않으면서, 신경 통증감각 수용체(TRPV1: Transient Receptor Potential family V 1) 길항제로 작용하여, 매트릭스 메탈로프로티아제(matrix metalloprotease) 활성 억제 효과를 발휘하는 바, 피부 노화 방지용 조성물의 유효 성분으로 적합하게 사용될 수 있다.
피부 노화 방지-
公开(公告)号：KR1020120027432A
公开(公告)日：2012-03-21
申请号：KR1020117031657
申请日：2010-06-18
Applicant: (주)아모레퍼시픽
CPC classification number: A23L33/105 , A23V2002/00 , A23V2200/318
Abstract: PURPOSE: Health food or pharmaceutical composition including containing a chestnut skin extract is provided to reduce the pruritus of a user. CONSTITUTION: Health food or pharmaceutical composition contains 0.005-80wt% of chestnut skin extract for reducing or controlling the pruritus of a user. The chestnut skin is selected from the inner skin, the outer skin, or their mixture. The chestnut skin extract is obtained by extracting the chestnut skin using water, low class alcohol having 1-4 carbons, 1,3-butyl glycol, or their mixed solution.
Abstract translation: 目的：提供包含栗子皮肤提取物的保健食品或药物组合物，以减少使用者的瘙痒。 规定：保健食品或药物组合物含有0.005-80wt％的栗子皮肤提取物，用于减少或控制使用者的瘙痒。 板栗皮肤选自内皮，外皮或其混合物。 栗子皮提取物是通过使用水，含1-4碳的低级醇，1,3-丁二醇或它们的混合溶液提取栗子皮来获得的。
-
公开(公告)号：KR1020100104343A
公开(公告)日：2010-09-29
申请号：KR1020090022704
申请日：2009-03-17
Applicant: (주)아모레퍼시픽
IPC: A61K31/353 , A61K8/49 , A61P17/10 , A61Q19/08
Abstract: PURPOSE: A composition for relieving skin irritation is provided to suppress expression of inflammatory intermediate factor. CONSTITUTION: A composition for relieving skin irritation contains a compound of chemical formula 1, isomer or pharmaceutically acceptable salt thereof as an active ingredient. The composition is used for relieving skin irritation including skin dryness, inflammation, erythema, or itchness. The skin irritation by an external skin ingredient is skin irritation by retinoid or surfactant. The retinoid is retinol, retinal or retinoic acid. An external use skin formulation for treating dermatitis contains the composition.
Abstract translation: 目的：提供缓解皮肤刺激的组合物，以抑制炎性中间因子的表达。 构成：用于缓解皮肤刺激的组合物含有化学式1化合物，其异构体或其药学上可接受的盐作为活性成分。 该组合物用于缓解皮肤刺激，包括皮肤干燥，炎症，红斑或瘙痒。 外用皮肤成分引起的皮肤刺激是类视黄醇或表面活性剂引起的皮肤刺激。 类视色素是视黄醇，视黄醛或视黄酸。 用于治疗皮炎的外用皮肤制剂含有该组合物。
-
30.发明授权2,4,5-삼중치환-1,3-티아졸 유도체 및 약제학적으로 허용가능한 그의 염, 그의 제조방법 및 그를 유효성분으로함유하는 ＳＰＣ 수용체 활성으로 유발되는 염증관련 질환치료제 有权新的2,4,5-三唑-3-基噻唑衍生物及其药物可接受的盐，其制备方法，用于由含有2,4,5-三唑基-1,3-噻唑衍生物的SPC活性诱导的抗炎性疾病的治疗剂 有效的成分
公开(公告)号：KR100903974B1
公开(公告)日：2009-06-25
申请号：KR1020070097553
申请日：2007-09-27
Inventor： 공영대 , 조희영 , 전문국 , 이태호 , 최길돈 , 공재양 , 정대영 , 황순희 , 김정주 , 이창훈 , 고재영 , 노민수 , 한은실 , 김형준 , 김혁 , 윤준원 , 모주현 , 김도훈
IPC: C07D277/44 , C07D417/04 , C07D417/12 , A61K31/426
CPC classification number: C07D277/46 , C07D417/04 , C07D417/12
Abstract: 본 발명은 하기 화학식 1로 표시되는 2,4,5-삼중치환-1,3-티아졸 유도체 및 약제학적으로 허용 가능한 그의 염, 그의 제조방법 및 그를 유효성분으로 함유하는 SPC 수용체 활성으로 유발되는 염증관련 질환에 유용한 그의 용도에 관한 것이다.
본 발명의 2,4,5-삼중치환-1,3-티아졸 유도체는 사람으로부터 유래된 진피세포 및 마우스를 이용한 동물실험을 통하여 항염증 효과를 검색한 결과, SPC 수용체에 대한 우수한 억제활성을 규명함으로써, 상기 2,4,5-삼중치환-1,3-티아졸 유도체 및 약제학적으로 허용 가능한 그의 염을 유효성분으로 함유하여 SPC 수용체 활성으로 유발되는 아토피성 피부염, 기타 질환에서 나타나는 염증, 소양증 또는 피부 감염증에 유효한 염증관련 질환 치료제로서 유용하게 활용될 수 있다.
(상기 식에서, R
1 , R
2 , 및 R
3 는 명세서에서 정의한 바와 같다.)
1,3-티아졸, 스핀고실포스포릴콜린, 아토피 피부염, 염증치료제
-
-
-
-
-
-
-
-
-
Search Results
80
records
(took 0.028 seconds)
